Loading
TI
Tevogen Inc. Stock: price and insider trades · United States
US·Mcap US$46M
No insider purchase over the last 90 days. The latest, by Desai Kirti, was filed 13 Jun 2024.
Tevogen Inc.: what insiders have been doing
Tevogen Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Tevogen Inc. logged 18 filings by 8 insiders.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €127. The largest single trade was a sale of €127 by Flomenberg Neal, published on 17 March 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,458 companies, median 22 filings), a count of 18 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 3 purchases and 8 sales.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
50
Thresholds
n/a
Buy Volume
€4,114
3 ops. · all time
Sell Volume
€18M
8 ops. · all time
Who traded when
BuySaleNeal Flomenberg4 sales
Ryan H. Saadi1 sale
Since the insiders bought
- +49.9%Entry US$41.35 · Close at T+365 US$62.00
- +32.9%Entry US$41.40 · Close at T+365 US$55.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.07
Analyst consensus
Income statement
EBITDA-US$25.6M
Net income-US$26.3M0.0% margin
Valuation
Beta0.20
Balance sheet & cash
Market capUS$46M
Total debtUS$7.5M
Free Cash Flow-US$12.4M
Profitability & ownership
ROA-297.4%
% insiders72.1%
% institutions1.6%
Last declaration on 16 September 2026
Declarations50 total
750,000 shares0Common StockSEC:0001123292-26-001312:0
8,000,000 shares0Common StockSEC:0001123292-26-001313:0
75,000 shares0Common StockSEC:0001123292-26-001304:0
75,000 shares0Common StockSEC:0001123292-26-001307:0
75,000 shares0Common StockSEC:0001123292-26-001306:0
75,000 shares0Common StockSEC:0001123292-26-001303:0
75,000 shares0Common StockSEC:0001123292-26-001305:0
40,000 shares0Common StockSEC:0001123292-26-000991:0
40,000 shares0Common StockSEC:0001123292-26-000994:0
40,000 shares0Common StockSEC:0001123292-26-000996:0
40,000 shares0Common StockSEC:0001123292-26-000990:0
40,000 shares0Common StockSEC:0001123292-26-000992:0
40,000 shares0Common StockSEC:0001123292-26-000993:0
1,220,000 shares0Common StockSEC:0001123292-26-000995:0
19 shares@ US$7.750.0% of flowCommon StockSEC:0001123292-26-000465:0
50,000 shares0Common StockSEC:0001123292-25-000765:0
300,000 shares0Common StockSEC:0001123292-25-000757:0
460,000 shares0Common StockSEC:0001123292-25-000755:0
20,000 shares0Common StockSEC:0001062993-25-014586:0
750,000 shares0Common StockSEC:0001062993-25-012327:0
8,000,000 shares0Common StockSEC:0001062993-25-012333:0
200,000 shares0Common StockSEC:0001062993-25-012331:0
300,000 shares0Common StockSEC:0001062993-25-012329:0
1,438,206 shares@ US$1.2399.9% of flowCommon StockSEC:0001062993-25-011293:0
232,968 shares@ US$1.0912.0% of flowCommon StockSEC:0001062993-25-005533:0
25 of 50 declarations
About Tevogen Inc.
Tevogen Inc. is a company focused on developing cell therapies to treat viral diseases and cancers. It concentrates on using T cell technology to provide innovative solutions in the healthcare sector.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
